Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364597 · ClinicalTrials.gov registry record · Phase 3
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 257
- Enrollment target
NCT01364597: Completed Phase 3 study, sponsored by UCB Pharma.
NCT01364597 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 257 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01364597, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 257 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
Primary Outcome
TEAEs are defined as AEs that had onset on or after the day of first BRV dose.
Interventions
- DRUG Brivaracetam (BRV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2011-08-01 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 3 |
What the finished NCT01364597 record still lists
NCT01364597 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam (BRV) is the first listed.
NCT01364597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01364597 about?
NCT01364597 is a clinical study titled "Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy". This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
What is the current status of trial NCT01364597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 257 participants. The study started on 2011-08-01. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT01364597?
The interventions under investigation include: Brivaracetam (BRV) (DRUG).
Who is sponsoring clinical trial NCT01364597?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01364597's enrollment target sits among peer trials
257 1238th of 2000 higher than 761 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI